Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration & beyond

Summary by The Manila Times
SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein...

2 Articles

The Manila TimesThe Manila Times
Reposted by
Laotian TimesLaotian Times
Lean Right

Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration & beyond

SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein...

·Manila, Philippines
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Laotian Times broke the news in on Monday, December 8, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Suzhou, China icon

Suzhou, China

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal